Approval, contemporary observations and a later label each keep their own date.
Reading Library · Anesthesia Epochs · 中文版
Watch the companion film
1972: Enflurane — FDA Approval and Clinical Questions · Watch on YouTube
Historical anchor: 1972. Date details and source qualifications are explained below.
Reading a regulatory milestone beside the observations of its time

In October 1972, Wendell C. Stevens discussed enflurane and isoflurane together in California Medicine. His brief account placed them at different stages: enflurane already had considerable clinical use, while isoflurane remained under intensive investigation.[2] The statement captures a contemporary perspective. Without a geographic denominator or patient count, it cannot tell us how widely either agent had spread.
An official record supplies a more precise, narrower milestone. Drugs@FDA lists August 28, 1972 as the original approval date for Ethrane, the enflurane product under NDA 017087, with a new molecular entity classification.[1] This dates a United States regulatory action. It does not date the compound's synthesis, first administration to a person, or first use anywhere in the world.

Stevens presented the new halogenated ethers against concerns about flammability and toxicity in existing agents. Similar physical properties, he observed, could coexist with different pharmacological effects.[2] That comparison gives this milestone a specific connection to this site's isoflurane synthesis article: making a candidate, evaluating it clinically, and obtaining approval are separate events. The connection does not imply that enflurane's approval caused isoflurane's synthesis.
The contemporary column also discussed EEG changes and muscle twitching during enflurane anesthesia, in relation to deeper anesthesia, hypocarbia, or both.[2] Its optimistic interpretation belongs to that historical account. It should not be carried forward as an unrestricted assurance of safety.

The FDA's archived January 2010 label describes a nonflammable liquid delivered by vaporization. It lists seizure disorders and susceptibility to malignant hyperthermia among its contraindications, and addresses EEG and seizure risks associated with anesthetic depth and low arterial carbon dioxide.[3] This is a later document. The FDA history page does not supply the original 1972 label, so its later wording cannot be assigned to the day of approval.
The historical record is clearer when each document keeps its date and purpose. The approval entry fixes a regulatory event; clinical writing preserves what authors observed and how they interpreted it. Neither needs to be made into a claim that all subsequent questions had been settled. This account concerns medical history, not instructions for administering an anesthetic.

Sources and reading limits
- FDA. Drugs@FDA: NDA 017087, Ethrane. Original approval entry and supplement history read; date cross-checked with the official openFDA record. The original 1972 label and review dossier are not covered.
- Stevens WC. New Halogenated Anesthetics: Enflurane and Isoflurane. California Medicine. 1972;117(4):47. PMID 18730834. Complete one-page column read from the original scan; neighboring articles excluded. Contemporary commentary, not a comparative trial.
- FDA archive. Ethrane (enflurane, USP), label revised January 2010. Nine pages fully read; description p1, contraindications p3, warnings p4 and revision date p9 support this account. A later label, not the 1972 original or current prescribing guidance.
Images are modern editorial creations, not historical packaging, approval letters or original EEG records.
Continue exploring
Related reading connects shared questions and contexts; it does not by itself establish historical influence.
The Source Room · About & Editorial Method
Sources and reading limits are stated above. Illustrations are labelled as original source images or AI-made. Historical accounts are educational; they are not current treatment instructions.